Intrarenal Complement System Transcripts in Chronic Antibody-Mediated Rejection and Recurrent IgA Nephropathy in Kidney Transplantation

Background: The complement system activation and regulation have been linked to post-transplant pathologies including chronic antibody mediated rejection (cAMR) and the recurrence of IgA nephropathy (ReIgAN) but distinct mechanisms remain to be elucidated. Methods: In this retrospective single center study, the outcome of kidney transplantation was studied in 150 patients with late histological diagnosis to be either cAMR or ReIgAN, 14 stable kidney grafts at 3 months and finally 11 patients with native kidney IgAN nephropathy. To study a role of complement cascade and regulation in cAMR and ReIgAN, the RNA was extracted from available frozen kidney biopsy samples and using RT-qPCR transcripts of 11 target genes along with clinical data were determined and compared with stable grafts at 3 months protocol biopsies or IgAN native kidney nephropathy. Immunohistologically, CD46 (MCP), and C5 proteins were stained in biopsies. Results: Interestingly, there were no differences in kidney graft survival between cAMR and ReIgAN since transplantation. cAMR was associated with significantly higher intragraft transcripts of C3, CD59, and C1-INH as compared to ReIgAN (p < 0.05). When compared to normal stable grafts, cAMR grafts exhibited higher C3, CD55, CD59, CFH, CFI, and C1-INH (p < 0.01). Moreover, ReIgAN was associated with the increase of CD46, CD55, CD59 (p < 0.01), and CFI (p < 0.05) transcripts compared with native kidney IgAN. Rapid progression of cAMR (failure at 2 years after biopsy) was observed in patients with lower intrarenal CD55 expression (AUC 0.77, 78.6% sensitivity, and 72.7 specificity). There was highly significant association of several complement intrarenal transcripts and the degree of CKD regardless the diagnosis; C3, CD55, CFH, CFI, and C1-INH expressions positively correlated with eGFR (for all p < 0.001). Neither the low mRNA transcripts nor the high mRNA transcripts biopsies were associated with distinct trend in MCP or C5 proteins staining. Conclusions: The intrarenal complement system transcripts are upregulated in progressively deteriorated kidney allografts.

[1]  J. Schmid.  Banff , 2019, San Antonio Review.

[2]  L. Peruzzi,et al.  Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy. , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  V. Jha,et al.  Allo-specific immune response profiles indicative of acute rejection in kidney allografts using an in vitro lymphocyte culture-based model , 2018, Clinical and Experimental Nephrology.

[4]  Guoyuan Lu,et al.  Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study , 2017, BMC Nephrology.

[5]  O. Viklicky,et al.  Complement in Kidney Transplantation , 2017, Front. Med..

[6]  G. Parry,et al.  Effect of the Anti‐C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody–Induced Complement Activation—A Preclinical In Vitro Study , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  A. Sharif,et al.  The Spectrum of Renal Allograft Failure , 2016, PloS one.

[8]  L. Sénécal,et al.  Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature , 2016, Case reports in transplantation.

[9]  Chao Lu,et al.  Retrospective study , 2016, Medicine.

[10]  A. Loupy,et al.  C1 Inhibitor in Acute Antibody‐Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  J. Moon,et al.  A Promoter Polymorphism in the CD46 Complement Regulatory Protein Gene Is Associated With Acute Renal Allograft Rejection. , 2016, Transplantation proceedings.

[12]  Krzysztof Kiryluk,et al.  Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese. , 2016, Journal of the American Society of Nephrology : JASN.

[13]  M. Daha,et al.  Role of complement in IgA nephropathy , 2015, Journal of Nephrology.

[14]  P. Heeger,et al.  Effects of complement activation on allograft injury , 2015, Current opinion in organ transplantation.

[15]  N. Sheerin,et al.  Complement activation in progressive renal disease. , 2015, World journal of nephrology.

[16]  M. Haas,et al.  A Phase I/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients , 2015, Transplantation.

[17]  D. Maixnerova,et al.  Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994–2011 , 2015, Journal of Nephrology.

[18]  M. Haas.  An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts , 2014, Current opinion in organ transplantation.

[19]  A. Mallett,et al.  Atypical HUS associated with severe, unexpected antibody‐mediated rejection post kidney transplant , 2014, Nephrology.

[20]  C. Farrar,et al.  Mechanisms of rejection: role of complement , 2014, Current opinion in organ transplantation.

[21]  D. Rush,et al.  Banff 2013 Meeting Report: Inclusion of C4d‐Negative Antibody‐Mediated Rejection and Antibody‐Associated Arterial Lesions , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  X. Jouven,et al.  Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.

[23]  S. Quaglini,et al.  The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  R. Colvin,et al.  Banff 2011 Meeting Report: New Concepts in Antibody‐Mediated Rejection , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  T. Fujita,et al.  Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function , 2011, BMC nephrology.

[26]  M. Stegall,et al.  Terminal Complement Inhibition Decreases Antibody‐Mediated Rejection in Sensitized Renal Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  D. Rush,et al.  Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure , 2010, Transplantation.

[28]  L C Racusen,et al.  Banff ’09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  P. Halloran,et al.  Antibody‐Mediated Microcirculation Injury Is the Major Cause of Late Kidney Transplant Failure , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  J. Köhl,et al.  The role of the anaphylatoxins in health and disease. , 2009, Molecular immunology.

[31]  D. Birmingham,et al.  Expression of the Decay-Accelerating Factor (CD55) in Renal Transplants—A Possible Prediction Marker of Allograft Survival , 2009, Transplantation.

[32]  M. Daha,et al.  Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. , 2009, Kidney international.

[33]  A. Griesemer,et al.  Upregulation of CD59: Potential Mechanism of Accommodation in a Large Animal Model , 2009, Transplantation.

[34]  F. Cosio,et al.  Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[35]  D. Budai,et al.  CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b‐8 as well as C5b‐9 , 2002, The Journal of physiology.

[36]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[37]  W. Fischer,et al.  Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). , 1999, Journal of immunology.

[38]  T. Geiser,et al.  Activation of human neutrophils by C3a and C5A Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst , 1994, FEBS letters.

[39]  E. Ritz,et al.  Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. , 1987, Kidney international.

[40]  K. Hongo,et al.  A case report and review of the literature , 2006, Journal of Neuro-Oncology.

[41]  J. Nagy,et al.  Membrane attack complex and membrane cofactor protein are related to tubulointerstitial inflammation in various human glomerulopathies. , 1997, Nephron.